Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors in the central anxious system, conolidine modulates alternate molecular targets. A Science Improvements research uncovered that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://ammonr986rsu7.dreamyblogs.com/profile